



## **G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference**

April 6, 2022

RESEARCH TRIANGLE PARK, N.C., April 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey and Raj Malik, M.D., G1's Chief Executive Officer and Chief Medical Officer, respectively, will participate in a fireside chat during the 21st Annual Needham Virtual Healthcare Conference. The fireside chat will take place on Wednesday April 13, 2022, at 11:00 AM EDT. This meeting is being held virtually, and a live webcast will be accessible on the [Events & Presentations page](https://www.g1therapeutics.com/events-presentations) of <http://www.g1therapeutics.com>.

### **About G1 Therapeutics**

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit [www.g1therapeutics.com](http://www.g1therapeutics.com) and follow us on Twitter [@G1Therapeutics](https://twitter.com/G1Therapeutics).

### **Contacts:**

Will Roberts

Vice President, Investor Relations & Corporate Communications

919-907-1944

[wroberts@g1therapeutics.com](mailto:wroberts@g1therapeutics.com)



Source: G1 Therapeutics